• May 18, 2022
 Video: Cornyn Calls for Examination of Patent Process for Prescription Drugs

Video: Cornyn Calls for Examination of Patent Process for Prescription Drugs

WASHINGTON – During a Senate Finance Committee hearing on drug pricing, U.S. Senator John Cornyn (R-TX) today questioned AbbVie CEO Rick Gonzalez on the company’s use of patents to protect their prescription drugs.

Excerpts of Sen. Cornyn’s line of questioning are below, and video can be found above. 


“We want to make sure that we maintain the most innovative pharmaceutical drug companies in the world because we want to provide life-saving cures for our people, and I get the idea that that’s the purpose of the patent system, which is to protect the exclusivity of that drug that you’ve sunk a lot of money into the research and development for.”

 “But at some point, that patent has to end, that exclusivity has to end, so that the patients can get access to those drugs at a much cheaper cost.”

“I think this is an area that we need to look into through our Judiciary Committee authority as well.”


Senator John Cornyn, a Republican from Texas, is a member of the Senate Finance, Intelligence, and Judiciary Committees.

Guest Columnist

Guest Columnists are residents who feel so strongly about a news event, a story or some other issue, that they decided to put their thoughts to paper - or computer screens. Or they are writers who have made their work available via other channels and we feature their work here, with permission. If you'd like to submit a column, please contact us at news@epheraldpost.com

Related post


  • Looks like someone didn’t get their big Pharma contribution this year…

    • Absolutely! coming from the same stooge that want’s a $one dollar coin to honor the Bush family!
      After watching the Michael Cohen congressional hearing today!
      Better a $one dollar Michael Cohen coin for telling the truth about Donald Trump!

  • John Cornyn is going to be around for a very long long time in the United States senate! longer than Utah’s Orrin Hatch.

Comments are closed.